Cytiva's X-Platform Bioreactors Boost Process Efficiency, Paving the Way for Future Biomanufacturing Breakthroughs

Global biotechnology leader builds on Xcellerex heritage to now offer X-platform bioreactors. X-platform bioreactors can be used for monoclonal antibodi...

April 19, 2023 | Wednesday | News
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol

As disclosed in September 2022, Avenue received meeting minutes from the FDA regarding a Type A meeting conducted on August 9, 2022, for IV Tramadol. At th...

April 18, 2023 | Tuesday | News
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

In April 2022, Telix secured the exclusive worldwide rights to develop and commercialise radiolabelled forms of olaratumab for the diagnosis and treatment ...

April 17, 2023 | Monday | News
Atmo Biosciences strengthens U.S. focus with new board appointment and establishment of San Diego office

The increased presence in the U.S. comes as Atmo Biosciences prepares to begin a multi-site pivotal study to support a U.S. Food and Drug Administration (F...

April 17, 2023 | Monday | News
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.

PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions   Prometheus Biosciences&rs...

April 17, 2023 | Monday | News
Regulus Therapeutics Completes Enrollment in Phase 1b MAD Trial of RGLS8429 for ADPKD Treatment

"Completion of enrollment in the first cohort of the Phase 1b MAD study is an important milestone in the development of this novel treatment for ADPKD," sa...

April 13, 2023 | Thursday | News
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI

Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) fo...

April 09, 2023 | Sunday | News
Bispecific Antibodies: Successes, Challenges, and Strategies

Relapsed or refractory precursor B-cell acute lymphoblastic leukemia Bleeding due to hemophilia A Non-small cell lung cancer Unresectable or metastati...

April 09, 2023 | Sunday | News
Morphological Profiling: A Scalable Approach to Monitor Immune Cell Activity

Conventional high-content screening experiments typically focus on extracting imaging data relating to predefined, specific features to identify drugs or d...

April 09, 2023 | Sunday | News
Cell Expansion Market Analysis

The rising prevalence of chronic diseases coupled with increasing research activities for cell-based research is found to be the major factor driving the...

April 07, 2023 | Friday | Analysis
Accord BioPharma's Biosimilar Trastuzumab HLX02 BLA Accepted by US FDA

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...

April 06, 2023 | Thursday | News
Vertex, CRISPR submit BLAs to FDA for exa-cel in sickle cell and beta thalassemia

-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023-   -Vertex Pharmac...

April 04, 2023 | Tuesday | News
Campbell Neurosciences Announces Novel Mechanistic Data on CampbellCell Stem Cell Therapy for Schizophrenia

Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrati...

April 04, 2023 | Tuesday | News
The World's Second Approved Biosimilars of Denosumab (MAILISHU)

MAILISHU is the world's second approved Biosimilars of Denosumab for the osteoporosis in postmenopausal women at high risk of fracture. The drug can signif...

April 03, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close